Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table

Grosset, K., Needleman, F., Macphee, G. and Grosset, D. (2004) Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Movement Disorders, 19(11), pp. 1370-1374. (doi:10.1002/mds.20210) (PMID:15389984)

Full text not currently available from Enlighten.

Abstract

Of 99 patients on ergot‐derived dopamine agonists informed about possible long‐term side effects, switching to a nonergot was undertaken in 88 (89%). There were adverse events in 26%. After 11 months, 82% were on their switch agonist and 93% were on any agonist. Switching dopamine agonists is feasible in this population.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:MacPhee, Dr Graeme and Grosset, Dr Donald and Grosset, Dr Katherine
Authors: Grosset, K., Needleman, F., Macphee, G., and Grosset, D.
College/School:College of Medical Veterinary and Life Sciences > Institute of Neuroscience and Psychology
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Movement Disorders
Publisher:Wiley
ISSN:0885-3185
ISSN (Online):1531-8257
Published Online:11 June 2004

University Staff: Request a correction | Enlighten Editors: Update this record